BioPharma Credit (LSE:BPCR) FCF Margin % : 140.22% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioPharma Credit's Free Cash Flow for the six months ended in Dec. 2022 was $161.5 Mil. BioPharma Credit's Revenue for the six months ended in Dec. 2022 was $115.2 Mil. Therefore, BioPharma Credit's FCF Margin % for the quarter that ended in Dec. 2022 was 140.22%.

As of today, BioPharma Credit's current FCF Yield % is 17.75%.

The historical rank and industry rank for BioPharma Credit's FCF Margin % or its related term are showing as below:

LSE:BPCR' s FCF Margin % Range Over the Past 10 Years
Min: 63.57 Med: 102.99 Max: 111.49
Current: 100.02

During the past 7 years, the highest FCF Margin % of BioPharma Credit was 111.49%. The lowest was 63.57%. And the median was 102.99%.

LSE:BPCR's FCF Margin % is ranked better than
78.61% of 1557 companies
in the Asset Management industry
Industry Median: 17 vs LSE:BPCR: 100.02

BioPharma Credit FCF Margin % Historical Data

The historical data trend for BioPharma Credit's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit FCF Margin % Chart

BioPharma Credit Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

105.96

63.57

109.62

100.02

111.49

BioPharma Credit Semi-Annual Data
	Jun17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Dec23
FCF Margin %	Get a 7-Day Free Trial							76.65	145.66	32.95	140.22	-

Competitive Comparison of BioPharma Credit's FCF Margin %

For the Asset Management subindustry, BioPharma Credit's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioPharma Credit's FCF Margin % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's FCF Margin % falls into.

BioPharma Credit FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioPharma Credit's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	123.182	/	110.487
	=	111.49 %

BioPharma Credit's FCF Margin for the quarter that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	161.526	/	115.194
	=	140.22 %

BioPharma Credit FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPharma Credit (LSE:BPCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines